Table 2.

Univariate Cox proportional hazard analyses for OS in NSCLC patients from the SOC and DCVAC arms in SLU01.

SOC arm				DCVAC arm
Variable	HR (95% CI)	p-value		Variable	HR (95% CI)	p-value
PLA2G6	0.1 (0.01–0.5)	0.002		CD28	0.4 (0.2–0.6)	<0.001
GATA3	0.45 (0.3–0.8)	0.007		CD3E	0.4 (0.2–0.6)	<0.001
LILRB1	2.6 (1.3–5.4)	0.008		LILRB1	3.1 (1.7–5.8)	<0.001
LTA	0.5 (0.3–0.9)	0.011		STAT4	0.4 (0.2–0.7)	<0.001
IFI35	2 (1.2–3.5)	0.011		CD8A	0.6 (0.4–0.8)	<0.001
HAVCR	2.6 (1.2–5.7)	0.019		FLT3LG	0.4 (0.2–0.7)	<0.001
CD86	2.8 (1.2–6.7)	0.021		CD40LG	0.5 (0.3–0.7)	0.001
RORC	0.7 (0.5–0.9)	0.026		FOXP3	0.6 (0.4–0.8)	0.001
KLRB1	0.6 (0.3–0.9)	0.036		KLRB1	0.5 (0.3–0.8)	0.002
CD28	0.45 (0.21–0.95)	0.037		IL15	3.1 (1.5–6.6)	0.002
CD269	1.4 (1–2)	0.038		CD68	1.9 (1.3–3)	0.003
CXCR3	0.6 (0.3–0.9)	0.043		TIGIT	0.6 (0.4–0.8)	0.003
CXCL16	2 (1–4)	0.041		CCL5	0.6 (0.4–0.8)	0.003
IL2	0.8 (0.6–1)	0.045		GATA3	0.5 (0.3–0.8)	0.004
				KLRF1	0.5 (0.3–0.8)	0.006
				PLA2G6	0.4 (0.2–0.8)	0.008
				CTSW	0.6 (0.4–0.9)	0.011
				NCR3	0.6 (0.4–0.9)	0.012
				IL21R	0.5 (0.3–0.9)	0.014
				CTLA4	0.6 (0.4–0.9)	0.014
				IL12A	0.6 (0.5–0.9)	0.014
				STAT6	2.3 (1.2–4.6)	0.017
				SMAD3	0.4 (0.2–0.9)	0.018
				TBX21	0.6 (0.4–0.9)	0.023
				IL10	1.3 (1–1.5)	0.024
				CD86	1.8 (1.1–3.2)	0.027
				CCR4	0.7 (0.4–0.9)	0.028
				IFI35	1.6 (1–2.4)	0.032
				TNFRSF18	0.6 (0.4–0.9)	0.033
				XCL2	0.7 (0.5–1)	0.039

OS = overall survival; NSCLC = non-small cell lung cancer; SOC = standard of care chemotherapy; DCVAC, dendritic cell-based vaccination; HR = hazard ratio; CI = confidence interval